Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platanus occidentalis pollen is a non-standardized allergenic extract derived from the pollen of the American sycamore tree (Platanus occidentalis). [9] It is utilized for both the diagnosis and treatment of Type I hypersensitivity reactions (allergies) to this specific pollen. [2] For diagnostic purposes, it is administered via percutaneous or intradermal skin tests to elicit a localized allergic reaction, confirming sensitivity. [2] For therapeutic use, it is a key component of allergen immunotherapy (allergy shots), where gradually increasing doses are administered subcutaneously to desensitize the immune system and reduce the allergic response over time. [2, 3] This biological extract is manufactured by companies including Greer Laboratories, Inc. and is available as a single-allergen solution or as part of tree pollen mixtures. [9, 13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Platanus occidentalis pollen.